

# TB:HIV

## an international prospective observational study



### Newsletter: September 2014


#### Dear TB:HIV Study Investigators,

We hope you have all had a pleasant summer. Below, please find an update on the TB:HIV study status.

#### FOLLOW-UP (FU) STATUS:

In mid-June, 2014, we sent out a new batch of FU forms (6, 12, and 24 months FU forms) and the **deadline** for returning these was **1 September, 2014**. If you have FU forms not yet returned to the coordinating centre, we kindly ask you to do this as soon as possible. FU data is essential for being able to move the study forward with scientific analyses.

If you have any questions regarding FU forms, please contact Bitten Aagaard ([bitten.aagaard@regionh.dk](mailto:bitten.aagaard@regionh.dk)).



#### LOSS TO FOLLOW-UP (LTFU):

It remains essential to the study that we collect as complete FU data as possible. LTFU may be overcome by contacting other clinics in the area, dispensaries, NGOs, accessing death registries etc. to find any information on patients that are currently LTFU. We strongly encourage Investigators to prioritize this in order to minimize LTFU.

#### MYCOBACTERIAL SAMPLES (Mtb samples):

We encourage all investigators to arrange storage of and send us Mycobacterial samples cultured from the participating patients. Each sample is reimbursed by 30 Euro and shipment costs will be covered. Please contact us when you have samples ready for shipment.

#### SCIENTIFIC UPDATE:

We are happy to announce that an abstract presenting baseline data of the patients included to the study has been

#### Upcoming deadlines and tasks:

ASAP and no later than **1 September, 2014**:

- Complete and send us FU forms sent to your site in June, 2014.
- Complete and send us IRIS forms for patients who have developed IRIS.
- Complete and send us CoDe forms for those patients who have died.

#### Upcoming conferences and scientific meetings:

- HIV Drug Therapy, Glasgow 2-6 November, 2014. TB:HIV study oral presentation will be given 4 November, scheduled at 15.15. Title: *Major challenges in clinical management of TB/HIV coinfecting patients in Eastern Europe compared with Western Europe and Latin America*.
- TB:HIV Study Investigator/Steering Committee meeting during the HIV Drug Therapy conference, 3 November, 2014, from 12.00-13.00. Location: Morar room. Lunch will be served.

#### Contacts for the Coordinating Centre (CHIP)

##### Case Report Forms:

Bitten Aagaard:  
[bitten.aagaard@regionh.dk](mailto:bitten.aagaard@regionh.dk)

**Project Coordinator:** Anne Marie Werlinrud Efsen:

[anne.marie.werlinrud.efsens@regionh.dk](mailto:anne.marie.werlinrud.efsens@regionh.dk)

**Senior Coordinator:** Daria Podlekareva:

[daria.podlekareva@regionh.dk](mailto:daria.podlekareva@regionh.dk)

**Study leader:** Ole Kirk:

[Ole.Kirk@regionh.dk](mailto:Ole.Kirk@regionh.dk)

#### TB:HIV Study Group

Central /Northern Europe:

Belgium: Brussels

Denmark: Danish HIV Cohort

France: Aquitaine Cohort

Switzerland: Swiss HIV Cohort

United Kingdom: Cardiff, Leicester, London,

baseline data of the patients included to the study has been accepted as an oral presentation at the HIV Drug Therapy Glasgow conference (2-6 November, 2014), and the presentation is scheduled for 4 November at 15.15. The title of the presentation is: *Major challenges in clinical management of TB/HIV coinfecting patients in Eastern Europe compared with Western Europe and Latin America.*

A face-to-face TB:HIV Study Investigator/Steering Committee meeting will be held during the conference and we hope that many of you will have a chance to join us for this meeting scheduled for 3 November from 12.00-13.00.

Further, a manuscript is currently being finalized presenting characteristics of patients at enrolment and will be submitted for publication shortly. We believe this manuscript brings novel and important messages on usage of empiric anti-TB therapy and presence of anti-TB drug resistance at time of TB diagnosis with the Eastern European region being the main focus area.

The manuscript on the results of the health care survey from last year has also been finalised and was submitted for publication some months ago. We will keep you updated on the development of both manuscripts.

Again, we would like to emphasize that FU data will be extremely important to further elucidate the course of treatment and outcome thereof for these patients.

We are looking forward to seeing as many as possible of you during the HIV Drug Therapy conference in Glasgow in November and thank you for a continuous fruitful collaboration!



Manchester, Sheffield  
Eastern Europe:  
Belarus: Gomel, Minsk, Svetlogorsk  
Estonia: Ida-Viru county  
Georgia: Tbilisi  
Latvia: Riga  
Lithuania: Vilnius  
Poland: Bialystok, Warsaw, Wroclaw, Poznań, Krakow  
Romania: Bucharest  
Russia: Novgorod the Great, St. Petersburg, Samara  
Ukraine: Crimea  
Latin America:  
Argentina: Buenos Aires  
Chile: Santiago  
México: México D.F.  
Southern Europe:  
Italy: Bari, Brescia, Genova, Monza, Palermo, Rome, Sanremo  
Spain: Barcelona, Madrid, San Sebastián

#### **TB:HIV Study Steering Committee**

M. Bruyand, J. A. Caylá, D. Duiculescu (†), H. Furrer, E. Girardi, M. H. Losso, J.D. Lundgren, R. Miller, J.M. Miro, N. Obel, A. Panteleev (Co-Chair), F. Post (Co-Chair), A. Skrahin, J. J. Toibaro

#### **Update from EuroCoord**

Please find the latest newsletter from EuroCoord at:

[www.eurocoord.net](http://www.eurocoord.net)



TB:HIV Study Coordinating Centre: Centre for Health and Infectious Disease Research (CHIP), Rigshospitalet, University of Copenhagen, Department of Infectious Diseases and Rheumatology, Section 2100, Finsencentret, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark, Tel: +45 35 45 57 57, Fax: +45 35 45 57 58, Web: [www.regionh.dk](http://www.regionh.dk) [www.cphiv.dk](http://www.cphiv.dk), e-mail: [tb-hiv.rigshospitalet@regionh.dk](mailto:tb-hiv.rigshospitalet@regionh.dk)